stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Free cash flow margin
Amylyx Pharmaceuticals, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −26,369.1% (fiscal 2021) to 2.80% (fiscal 2023); the current reading is higher than 83% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 233.50 |
| FY2024 | −233.5% | (236.30) |
| FY2023 | 2.80% | 823.30 |
| FY2022 | −820.5% | 25,548.62 |
| FY2021 | −26,369.1% | (20,700.20) |
| FY2020 | −5,668.9% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| LQDA Liquidia Corporation compare | 33.4% |
| TRLV Trulieve Cannabis Corp. compare | 22.4% |
| PBH Prestige Consumer Healthcare Inc. compare | 18.4% |
| PRGO Perrigo Company plc compare | 4.11% |
| HIMS Hims & Hers Health, Inc. compare | 3.22% |
| SUPN Indivior Pharmaceuticals Inc. compare | 2.26% |
| AMLX Amylyx Pharmaceuticals, Inc. | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement